Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

VRCA 12.06.2024

Full Press ReleaseSEC FilingsOur VRCA Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
  • 12.20.2024 - Verrica Provides Business and Operational Update
  • 12.09.2024 - Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 12.09.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.09.2024 - S-8 Securities to be offered to employees in employee benefit plans
  • 12.09.2024 - 8-K Current report
PDF Version

WEST CHESTER, Pa.,Dec. 06, 2024(GLOBE NEWSWIRE) --Verrica Pharmaceuticals Inc.(“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its development and commercialization partner, Torii Pharmaceutical Co. Ltd. (“Torii”), submitted a New Drug Application (“NDA”) of TO-208 (referred to as VP-102 and marketed as YCANTH®in theU.S.) for the treatment of Molluscum Contagiosum (“molluscum”) inJapan.

“Torii continues to be an outstanding partner in advancing TO-208 for the treatment of molluscum, and today’s NDA submission represents the next critical milestone towards bringing to market the first therapeutic for addressing this indication in Japan,” saidJayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica. “With an estimated prevalence of approximately 1.6 million cases, molluscum represents a large and underserved patient population inJapan, and we believe Torii’s therapeutic expertise and commercial infrastructure in dermatology will maximize the opportunity to address this significant unmet need.”

TO-208 is a skin disease treatment drug candidate containing cantharidin as an active ingredient. In the Phase 3 clinical study of TO-208 in patients with molluscum contagiosum (≥2 years old) inJapan, the primary endpoint of efficacy has met superiority to the vehicle. Furthermore, the safety profile of TO-208 in the study was consistent to prior studies inthe United Statesand there were no observed issues of tolerability for the application.

Torii and Verrica executed an exclusive license agreement for the development and commercialization of TO-208 for the treatment of molluscum and common warts inJapaninMarch 2021.

Verrica received manufacturing and marketing approval of VP-102 to treat molluscum contagiosum in theU.S.inJuly 2023. Verrica has marketed VP-102 under the brand name YCANTH®in theU.S.sinceAugust 2023and has completed a Phase 2 clinical study of VP-102 for the treatment of common warts and a Phase 2 clinical study of VP-102 for the treatment of external genital warts in theU.S.

About YCANTH®(VP-102)YCANTH®is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH®is the first and only commercially available product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people inthe United States, primarily children. Approval of YCANTH®was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH®was a safe and effective therapeutic for the treatment of molluscum. Approximately 228 million lives are eligible to receive YCANTH®covered by insurance. YCANTH®is available to all patients with and without insurance coverage for$25per treatment, and further financial assistance is available for patients in need. Please visitYCANTHPro.comfor additional information.

YCANTH®should only be administered by a trained healthcare professional. YCANTH®is not for home use.

AboutVerrica Pharmaceuticals Inc.Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH®(VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people inthe United States, primarily children. YCANTH®(VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.

Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about Verrica’s expectations with regard to the clinical development and potential commercialization of TO-208 for the treatment of molluscum inJapan, Torri’s ability to maximize the opportunity inJapan, the clinical development of YCANTH (VP-102) for additional indications, and the benefits of Verrica’s product candidates, including YCANTH (VP-102). These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year endedDecember 31, 2023, Verrica’s Quarterly Report on Form 10-Q for the quarter endedSeptember 30, 2024and other filings Verrica makes with theSEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com

Chris CalabreseLifeSci Advisorsccalabrese@lifesciadvisors.com

Primary Logo

Source: Verrica Pharmaceuticals Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com